arXiv subjects

Saram Abbas

Publications and source records attributed to Saram Abbas.

5 recordsLinked to original sources

arXiv2026

Training-Free Human-in-the-Loop Anomaly Detection via Memory Bank Correction

Anomaly detectors are hardest to deploy exactly where training data is scarcest: a newly commissioned production line has a handful of verified "golden" samples and no machine-learning engineer on the factory floor. We present a training-free human-in-the-loop framework in which a domain expert corrects a PatchCore detector by direct memory bank editing: no retraining, no gradients, no original training data. A false-positive correction inserts the reviewed image's normal patches through a self-calibrating novelty gate admitting only those beyond the median pool-normal nearest-neighbour distance. From a bank built on only ten golden samples, operator corrections close a median 66% of the gap to an uncorrected fully trained bank (mean 80%, raised by three categories that overshoot parity), significantly improving 12 of 15 MVTec AD categories and harming none: ten samples plus corrections outperform hundreds of samples without them. On already-trained banks the headroom is smaller and concentrated where the bank undersamples normal appearance (gated: toothbrush +0.10, metal nut +0.09, zipper +0.05, screw +0.05), and no category except grid is significantly harmed. Evaluation uses a held-out protocol (20 splits per category, Holm-corrected Wilcoxon), because corrected images entering the bank inflate naive evaluation toward AUROC 1.0 by memorisation. Passive and active querying are statistically indistinguishable; a matched-label-budget control attributes gains to deployment-time label production at 43% of exhaustive-review cost; a defect-memory extension fails decisively. Feedback is simulated from ground truth; live expert trials, where mislabelling is costliest on small banks, remain future work.

cs.LG↗

arXiv2026

Zero-Shot Adaptation of Medical Vision Foundation Models for High-Frequency Micro-Ultrasound Prostate Segmentation

Prostate cancer claims a life every 80 seconds. Early detection is needed to prevent disease progression, and both PSA density calculation and biopsy decisions rely on knowing the exact boundary of the gland. Conventional ultrasound at 6-12 MHz blurs this boundary, missing one in three high-risk cancers. Micro-ultrasound (29 MHz) improves resolution threefold but introduces dense acoustic speckle that obscures the outer wall; given the same image, two clinicians draw outlines differing by over 10% in area. Supervised methods are costly and generalise poorly across scanners. Can a foundation model segment the prostate with no training data? We present the first zero-shot pipeline for this modality: MedSAM, pre-trained on over 1.5 million medical images, localises the prostate; we then apply CLAHE to sharpen the outer wall, binary dilation to recover missed pixels, and Fourier smoothing (4 modes, s=1.05) to refine the boundary. MedSAM requires a spatial prompt, so we evaluate bounding-box and point-click strategies across 75 patients of the Micro-Ultrasound Prostate Segmentation dataset (2,621 slices). On the 20-patient held-out test set, the pipeline reduces mean boundary-distance error by 45% (Dice 0.749+/-0.043 to 0.865+/-0.029; HD95 217.2+/-36.9 to 120.1+/-26.1 px), reaching Dice 0.859 across the cohort. Its mean overlap shows no significant difference from the three non-expert rater groups (p>0.19), while segmenting 38-52% more consistently (lower inter-patient standard deviation). Point-click prompts fail regardless of placement (best Dice=0.350), because speckle gives no stable local contrast. Only an approximate bounding box is required, so any clinic can deploy it without data collection, annotation, or retraining.

cs.CV↗

arXiv2025

AI-Based Clinical Rule Discovery for NMIBC Recurrence through Tsetlin Machines

Bladder cancer claims one life every 3 minutes worldwide. Most patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC), yet up to 70% recur after treatment, triggering a relentless cycle of surgeries, monitoring, and risk of progression. Clinical tools like the EORTC risk tables are outdated and unreliable - especially for intermediate-risk cases. We propose an interpretable AI model using the Tsetlin Machine (TM), a symbolic learner that outputs transparent, human-readable logic. Tested on the PHOTO trial dataset (n=330), TM achieved an F1-score of 0.80, outperforming XGBoost (0.78), Logistic Regression (0.60), and EORTC (0.42). TM reveals the exact clauses behind each prediction, grounded in clinical features like tumour count, surgeon experience, and hospital stay - offering accuracy and full transparency. This makes TM a powerful, trustworthy decision-support tool ready for real-world adoption.

cs.LG↗

arXiv2025

Attention-enabled Explainable AI for Bladder Cancer Recurrence Prediction

Non-muscle-invasive bladder cancer (NMIBC) is a relentless challenge in oncology, with recurrence rates soaring as high as 70-80%. Each recurrence triggers a cascade of invasive procedures, lifelong surveillance, and escalating healthcare costs - affecting 460,000 individuals worldwide. However, existing clinical prediction tools remain fundamentally flawed, often overestimating recurrence risk and failing to provide personalized insights for patient management. In this work, we propose an interpretable deep learning framework that integrates vector embeddings and attention mechanisms to improve NMIBC recurrence prediction performance. We incorporate vector embeddings for categorical variables such as smoking status and intravesical treatments, allowing the model to capture complex relationships between patient attributes and recurrence risk. These embeddings provide a richer representation of the data, enabling improved feature interactions and enhancing prediction performance. Our approach not only enhances performance but also provides clinicians with patient-specific insights by highlighting the most influential features contributing to recurrence risk for each patient. Our model achieves accuracy of 70% with tabular data, outperforming conventional statistical methods while providing clinician-friendly patient-level explanations through feature attention. Unlike previous studies, our approach identifies new important factors influencing recurrence, such as surgical duration and hospital stay, which had not been considered in existing NMIBC prediction models.

cs.LG↗

arXiv2024

Reviewing AI's Role in Non-Muscle-Invasive Bladder Cancer Recurrence Prediction

Notorious for its 70-80% recurrence rate, Non-muscle-invasive Bladder Cancer (NMIBC) imposes a significant human burden and is one of the costliest cancers to manage. Current tools for predicting NMIBC recurrence rely on scoring systems that often overestimate risk and have poor accuracy. This is where Machine learning (ML)-based techniques have emerged as a promising approach for predicting NMIBC recurrence by leveraging molecular and clinical data. This comprehensive review paper critically analyses ML-based frameworks for predicting NMIBC recurrence, focusing on their statistical robustness and algorithmic efficacy. We meticulously examine the strengths and weaknesses of each study, by focusing on various prediction tasks, data modalities, and ML models, highlighting their remarkable performance alongside inherent limitations. A diverse array of ML algorithms that leverage multimodal data spanning radiomics, clinical, histopathological, and genomic data, exhibit significant promise in accurately predicting NMIBC recurrence. However, the path to widespread adoption faces challenges concerning the generalisability and interpretability of models, emphasising the need for collaborative efforts, robust datasets, and the incorporation of cost-effectiveness. Our detailed categorisation and in-depth analysis illuminate the nuances, complexities, and contexts that influence real-world advancement and adoption of these AI-based techniques. This rigorous analysis equips researchers with a deeper understanding of the intricacies of the ML algorithms employed. Researchers can use these insights to refine approaches, address limitations, and boost generalisability of their ML models, ultimately leading to reduced healthcare costs and improved patient outcomes.

cs.LG↗